Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology therapeutics,
merging the cytotoxic effect of conjugated payload with the high specific ability and …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Background Amivantamab plus carboplatin–pemetrexed (chemotherapy) with and without
lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor …

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …

The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is
concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite …

Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid
biopsy-based testing has proven to be highly beneficial for identifying actionable cancer …

Non-small cell lung cancer is a heterogeneous disease and molecular characterisation
plays an important role in its clinical management. Next-generation sequencing-based …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …